H. Lee Moffitt Cancer Center and Research Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, H. Lee Moffitt Cancer Center and Research Institute sits in the top decile of US sponsors by registered trial count (#72 of 15,742 sponsors by registered trial count).
H. Lee Moffitt Cancer Center and Research Institute: 502 sponsored US clinical trials, 82 recruiting.
H. Lee Moffitt Cancer Center and Research Institute sponsors 502 registered US clinical trials on ClinicalTrials.gov, 82 of them currently recruiting, and 280 completed. 5 of these trials are in Phase 3-4 (later-stage) and 335 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 12 trials.
Top-decile sponsor footprint
H. Lee Moffitt Cancer Center and Research Institute ranks in the top decile of sponsors by registered trial count (#72 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
280 of 344 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
502 total, page 6 of 11
Oncology Research Information Exchange Network (ORIEN) Lung Cancer Study
NCT02803333
Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder
NCT02901548
Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer
NCT03043599
FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas
NCT03042780
Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT
NCT03018223
Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors
NCT02948946
Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma
NCT02945800
Spanish-Language Smoking Cessation Trial
NCT02945787
Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer
NCT02973750
Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma
NCT02935309
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
NCT02829918
Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)
NCT02851056
Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas
NCT02829931
Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma
NCT02631590
Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)
NCT02722941
Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
NCT02652455
Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
NCT02611037
Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention
NCT02588339
Fermented Wheat Germ Extract in Women With Ovarian Cancer
NCT02411565
TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer
NCT02586675
Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide
NCT02502864
Dose Escalation Study of Preoperative SBRT for High Risk Prostate Cancer
NCT02572284
Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer
NCT02440425
Smoking-cessation: A Spanish-Language Clinical Trial
NCT02611076
AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer
NCT02513563
Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
NCT02575300
Cognitive Behavioral Intervention for Targeted Therapy Fatigue (CBT-TTF) Intervention
NCT02592447
Using MC1R Genotype to Impact Melanoma Risk Behavior
NCT03509467
Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas
NCT02313272
Assess Gamma H2AX Positivity in Circulating Prostate Cancer Cells Before and After Radium 223
NCT02981797
Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)
NCT02402764
A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML
NCT02403310
Smoking Cessation Self-Help for Dual Users of Tobacco Cigarettes and E-Cigarettes
NCT02416011
Pilot Testing of a Real-Time Oncogeriatric Teleconsultation System Using the Total Cancer Care™ Database
NCT02708381
Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer
NCT02292173
Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer
NCT02300610
Smoking Cessation for Cervical Cancer Survivors
NCT02157610
Focal Prostate Radio-Frequency Ablation
NCT02328807
Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus
NCT02283359
BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer
NCT02155088
Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease
NCT01795573
Capitalizing on a Teachable Moment to Promote Smoking Cessation
NCT02276664
Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases
NCT02187822
HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer
NCT02063724
Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma
NCT02186834
Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer
NCT02139358
Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma
NCT02218164
COGNUTRIN in Breast Cancer Survivors
NCT01823991
Translating Extinction Research to Improve Pharmacotherapy for Tobacco Dependence
NCT02202499
Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck
NCT02158234
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 167 |
| Phase 2 | 168 |
| Phase 3 | 3 |
| Phase 4 | 2 |
Therapeutic Areas
What is open in the H. Lee Moffitt Cancer Center and Research Institute pipeline
82 recruiting of 502 indexed (16% open); 280 completed (56%).
Phase mix: 5 late (III/IV) vs 335 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
H. Lee Moffitt Cancer Center and Research Institute: open-pipeline peers nationwide
Peers matched on 502 registered trials and 16% open enrollment, not the therapeutic-area sidebar.
H. Lee Moffitt Cancer Center and Research Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 502 trials (± recruiting share)
- National Heart, Lung, and Blood Institute (NHLBI) · 501 trials · 12% recruiting
- Gilead Sciences · 504 trials · 5% recruiting
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 490 trials · 10% recruiting
- Boehringer Ingelheim · 515 trials · 8% recruiting
Sponsors near 16% open enrollment (± trial volume)
- Case Western Reserve University · 16% recruiting · 141 trials
- Drexel University · 16% recruiting · 92 trials
- Atlantic Health System · 16% recruiting · 43 trials
- BioMarin Pharmaceutical · 16% recruiting · 80 trials
Related
What to do with this H. Lee Moffitt Cancer Center and Research Institute page
502 registered trials is a research-attention snapshot, not an endorsement of H. Lee Moffitt Cancer Center and Research Institute or any single study.
- 82 of H. Lee Moffitt Cancer Center and Research Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition H. Lee Moffitt Cancer Center and Research Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. H. Lee Moffitt Cancer Center and Research Institute pipeline card: 502 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.